BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bisschop C, de Heer E, Brouwers A, Hospers G, Jalving M. Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. Critical Reviews in Oncology/Hematology 2020;153:103044. [DOI: 10.1016/j.critrevonc.2020.103044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Czepczyński R, Szczurek J, Mackiewicz J, Ruchała M. Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma-Case Report. Front Oncol 2021;11:690443. [PMID: 34414110 DOI: 10.3389/fonc.2021.690443] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H. Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Curr Oncol 2021;28:1630-40. [PMID: 33925392 DOI: 10.3390/curroncol28030152] [Reference Citation Analysis]
3 Jiménez-Sánchez J, Bosque JJ, Jiménez Londoño GA, Molina-García D, Martínez Á, Pérez-Beteta J, Ortega-Sabater C, Honguero Martínez AF, García Vicente AM, Calvo GF, Pérez-García VM. Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers. Proc Natl Acad Sci U S A 2021;118:e2018110118. [PMID: 33536339 DOI: 10.1073/pnas.2018110118] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Franklin C, Wetter A, Baba HA, Theysohn J, Haubold J, Cosgarea I, Hadaschik E, Livingstone E, Zimmer L, Stoffels I, Klode J, Lodde G, Placke JM, Schadendorf D, Ugurel S. Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. Eur J Cancer 2021;150:119-29. [PMID: 33895683 DOI: 10.1016/j.ejca.2021.03.026] [Reference Citation Analysis]
5 Bratteby K, Shalgunov V, Herth MM. Aliphatic 18 F-Radiofluorination: Recent Advances in the Labeling of Base-Sensitive Substrates*. ChemMedChem 2021;16:2612-22. [PMID: 34169672 DOI: 10.1002/cmdc.202100303] [Reference Citation Analysis]
6 Kudura K, Dimitriou F, Mihic-Probst D, Muehlematter UJ, Kutzker T, Basler L, Förster R, Dummer R, Mangana J, Husmann L, Burger IA, Kreissl MC. Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients. Diagnostics (Basel) 2021;11:883. [PMID: 34063555 DOI: 10.3390/diagnostics11050883] [Reference Citation Analysis]
7 Van de Wiele C, Juanito G, Vander BK, Lawal I, De Spiegeleer B, Sathekge M, Maes A. Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. Semin Nucl Med 2021:S0001-2998(21)00042-8. [PMID: 34246450 DOI: 10.1053/j.semnuclmed.2021.06.010] [Reference Citation Analysis]
8 Malapelle U, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marchetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Crit Rev Oncol Hematol 2020;156:103118. [PMID: 33038627 DOI: 10.1016/j.critrevonc.2020.103118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 van Sluis J, de Heer EC, Boellaard M, Jalving M, Brouwers AH, Boellaard R. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. Eur J Nucl Med Mol Imaging 2021;48:1498-510. [PMID: 33099667 DOI: 10.1007/s00259-020-05068-3] [Reference Citation Analysis]